Pancreatic Cancer Research

ResearcherUniversity of Campania "Luigi Vanvitelli"No recent work listed

Angelica Petrillo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5489-5733; OpenAlex author ID A5088593159. Sources: OpenAlex.

Their work

Papers
8 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 1 paper

Papers 8

  1. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  2. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Last author DOI 10.3389/fonc.2021.695627↗
  3. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. First author DOI 10.3390/cancers13112797↗
  4. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? First author DOI 10.3390/cancers13174396↗
  5. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Co-author DOI 10.1007/s12032-019-1306-9↗
  6. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? First author DOI 10.3390/cancers11081095↗
  7. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… First author DOI 10.1155/2018/2373868↗
  8. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. Co-author DOI 10.1186/s12885-016-2671-9↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ferdinando De Vita · 5 shared papers, 2016–2021 · strength 0.46
  2. Michele Ghidini · 3 shared papers, 2019–2021 · strength 0.35
  3. Luca Pompella · 3 shared papers, 2018–2021 · strength 0.29
  4. Fausto Petrelli · 2 shared papers, 2019–2021 · strength 0.23
  5. Shelize Sadrudin Khakoo · 2 shared papers, 2019–2021 · strength 0.23
  6. Gianluca Tomasello · 2 shared papers, 2019–2021 · strength 0.23
  7. Annalisa Pappalardo · 2 shared papers, 2019–2021 · strength 0.22
  8. Michele Orditura · 3 shared papers, 2016–2019 · strength 0.20
  9. Fortunato Ciardiello · 2 shared papers, 2016–2019 · strength 0.13
  10. Gaël S. Roth · 1 shared paper, 2021 · strength 0.12
  11. Jean–Marc Phelip · 1 shared paper, 2021 · strength 0.12
  12. Julien Taı̈eb · 1 shared paper, 2021 · strength 0.12
  13. Nicolas Williet · 1 shared paper, 2021 · strength 0.12
  14. Teresa Troiani · 2 shared papers, 2016–2018 · strength 0.12
  15. Jole Ventriglia · 2 shared papers, 2016–2018 · strength 0.12
  16. Johannes Haybaeck · 1 shared paper, 2022 · strength 0.11
  17. Andreas Seeber · 1 shared paper, 2022 · strength 0.11
  18. Florian Kocher · 1 shared paper, 2022 · strength 0.11
  19. Alberto Puccini · 1 shared paper, 2022 · strength 0.11
  20. Mohamed E. Salem · 1 shared paper, 2022 · strength 0.11
  21. Richard M. Goldberg · 1 shared paper, 2022 · strength 0.11
  22. Heinz‐Josef Lenz · 1 shared paper, 2022 · strength 0.11
  23. Michael J. Hall · 1 shared paper, 2022 · strength 0.11
  24. Emil Lou · 1 shared paper, 2022 · strength 0.11
  25. Wolfgang Michael Korn · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.